Aura Biosciences Inc
AURA6.865USD
+0.125+1.86%
交易中 （美東）報價延遲15分鐘
344.82M總市值
虧損本益比TTM
關於 Aura Biosciences Inc 公司
Aura Biosciences, Inc. 是一家臨牀階段的生物技術公司。該公司致力於開發用於治療實體瘤的精準免疫療法，旨在保留患癌器官的功能。該公司正在開發一系列病毒樣藥物偶聯物 (VDC)，這是一類具有雙重作用機制的藥物，通過遞送細胞毒性有效載荷以產生急性壞死和激活次級免疫介導反應來促進癌細胞死亡。其主要候選藥物 bel-sar 正處於後期臨牀開發階段，用於治療原發性脈絡膜黑色素瘤和其他眼部腫瘤適應症患者，以及膀胱癌的早期臨牀開發。Bel-sar 由人乳頭瘤病毒 (HPV) 衍生的病毒樣顆粒 (VLP) 組成，與數百種紅外激光激活分子結合。該公司正在 III 期 CoMpass 試驗中評估 bel-sar 作爲早期脈絡膜黑色素瘤的一線治療。
公司簡介
公司代碼AURA
公司名稱Aura Biosciences Inc
上市日期Oct 29, 2021
CEODr. Elisabet (Eli) De Los Pinos, Ph.D.
員工數量106
證券類型Ordinary Share
年結日Oct 29
公司地址80 Guest Street
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02135
電話16175008864
網址https://aurabiosciences.com/
公司代碼AURA
上市日期Oct 29, 2021
CEODr. Elisabet (Eli) De Los Pinos, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Mark Plavsic, Ph.D.
Dr. Mark Plavsic, Ph.D.
Chief Technology Officer
Chief Technology Officer
209.46K
+72.92%
Ms. Amy Elazzouzi
Ms. Amy Elazzouzi
Senior Vice President - Finance
Senior Vice President - Finance
81.38K
-1.09%
Ms. Teresa Marie Bitetti
Ms. Teresa Marie Bitetti
Independent Director
Independent Director
21.00K
--
Mr. Conor Kilroy, J.D.
Mr. Conor Kilroy, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
16.84K
-29.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
13.00K
--
Mr. Antony Charles Mattessich
Mr. Antony Charles Mattessich
Independent Director
Independent Director
13.00K
--
Dr. Elisabet (Eli) De Los Pinos, Ph.D.
Dr. Elisabet (Eli) De Los Pinos, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Dr. Giovanni Mariggi, Ph.D.
Dr. Giovanni Mariggi, Ph.D.
Independent Director
Independent Director
--
--
Dr. J. Jill Hopkins, M.D.
Dr. J. Jill Hopkins, M.D.
Chief Medical Officer and President of Research & Development
Chief Medical Officer and President of Research & Development
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Mark Plavsic, Ph.D.
Dr. Mark Plavsic, Ph.D.
Chief Technology Officer
Chief Technology Officer
209.46K
+72.92%
Ms. Amy Elazzouzi
Ms. Amy Elazzouzi
Senior Vice President - Finance
Senior Vice President - Finance
81.38K
-1.09%
Ms. Teresa Marie Bitetti
Ms. Teresa Marie Bitetti
Independent Director
Independent Director
21.00K
--
Mr. Conor Kilroy, J.D.
Mr. Conor Kilroy, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
16.84K
-29.84%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
13.00K
--
Mr. Antony Charles Mattessich
Mr. Antony Charles Mattessich
Independent Director
Independent Director
13.00K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月25日 週日
更新時間: 5月25日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Matrix Capital Management Company, LP
11.17%
Frazier Life Sciences Management, L.P.
8.23%
Adage Capital Management, L.P.
7.88%
Long Focus Capital Management LLC
5.36%
BlackRock Institutional Trust Company, N.A.
5.15%
Other
62.21%
持股股東
持股股東
佔比
Matrix Capital Management Company, LP
11.17%
Frazier Life Sciences Management, L.P.
8.23%
Adage Capital Management, L.P.
7.88%
Long Focus Capital Management LLC
5.36%
BlackRock Institutional Trust Company, N.A.
5.15%
Other
62.21%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
22.57%
Hedge Fund
20.90%
Investment Advisor
15.23%
Venture Capital
8.56%
Private Equity
8.23%
Individual Investor
2.06%
Research Firm
0.39%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
21.93%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
205
48.39M
78.10%
+266.48K
2025Q1
206
42.86M
73.17%
-2.55M
2024Q4
195
42.39M
84.87%
-128.52K
2024Q3
180
42.50M
86.40%
-5.92M
2024Q2
172
45.50M
93.83%
-2.08M
2024Q1
161
44.88M
92.67%
-34.32K
2023Q4
149
42.45M
88.02%
+3.85M
2023Q3
135
34.73M
90.14%
-1.03M
2023Q2
133
34.30M
89.23%
+596.64K
2023Q1
120
32.28M
84.43%
+432.72K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Matrix Capital Management Company, LP
6.92M
11.17%
--
--
May 16, 2025
Frazier Life Sciences Management, L.P.
5.10M
8.23%
+5.10M
--
May 16, 2025
Adage Capital Management, L.P.
4.88M
7.88%
--
--
Mar 31, 2025
Long Focus Capital Management LLC
3.32M
5.36%
+781.81K
+30.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.19M
5.15%
-28.76K
-0.89%
Mar 31, 2025
Suvretta Capital Management, LLC
3.06M
4.93%
+325.43K
+11.91%
Apr 04, 2025
Medicxi Ventures (UK) LLP
3.04M
4.91%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
2.21M
3.57%
+487.62K
+28.31%
Mar 31, 2025
The Vanguard Group, Inc.
1.95M
3.15%
+34.60K
+1.80%
Mar 31, 2025
Lundbeckfond Ventures
1.75M
2.82%
-267.54K
-13.26%
Sep 30, 2024
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
AltShares Event-Driven ETF
1.11%
Harbor Human Capital Factor US Small Cap ETF
0.12%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
AltShares Event-Driven ETF
佔比1.11%
Harbor Human Capital Factor US Small Cap ETF
佔比0.12%
iShares Micro-Cap ETF
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
Avantis US Small Cap Equity ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
